Eli Lilly and Co.’s COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration (FDA) said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
Wednesday’s announcement takes away authorization from the last COVID-19 monoclonal antibody treatment, leaving Pfizer Inc.’s antiviral drug Paxlovid, Merck’s Lagevrio, and Gilead Sciences’ Veklury as treatments for the disease, besides convalescent plasma for some patients.
